Hemab Therapeutics
About
Hemab is a clinical-stage biotech company developing prophylactic therapies for severe bleeding and thrombotic disorders. Founded by biotech operators with Novo Nordisk roots, the company engineers antibody-based treatments aimed at preventing episodes before they occur in underserved rare-disease populations.
Investors 1
- Novo Holdings Venture Capital · Hellerup
Recent news
- Hemab Therapeutics closes $346.7 million IPO on Nasdaq under ticker COAG 2026-04-30 · Investing.com
- Hemab Therapeutics announces $157 million Series C financing to advance next-generation treatments for bleeding disorders 2025-10-27 · PR Newswire